Check Before You Invest : Mahavir Advanced Remedies Ltd

Snapshot

Q.1 Which industry/sub-sector does Mahavir Advanced Remedies Ltd belong to?

Mahavir Advanced Remedies Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Mahavir Advanced Remedies Ltd a good quality company?

Mahavir Advanced Remedies Ltd is a quality company, based on a 5-year financial track record.

Q.3 Is Mahavir Advanced Remedies Ltd undervalued or overvalued?

Mahavir Advanced Remedies Ltd appears Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Mahavir Advanced Remedies Ltd a good buy now?

Mahavir Advanced Remedies Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Return on capital employed (ROCE) of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Return on capital employed is 1.58% for FY-2014, which is above its 5-year historical median of -6.24%. The current ROCE is above its estimated weighted average cost of capital (WACC) of %, indicating value creation.

Q.2 Return on Asset of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Return on Asset is 1.58%, which is above its 5-year historical median of -4.42%, indicating improved asset utilization efficiency.

Q.3 Return on Equity (ROE) of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Return on equity is 1.58% for FY-2014, which is above its 5-year historical median of -6.57%, indicating the business is making better use of its shareholders capital.

Q.4 Gross Profit margin of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Gross profit margin which is the profit after deduction of direct costs, is 133.9% for FY-2014, which is above its 5-year median of -9.5%, indicating increasing margins.

Q.5 Operating Profit Margin of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -77.01% for FY-2014, which is below its 5-year median of -9.44% indicating decreasing margins.

Q.6 Net Profit Margin of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Net Profit Margin is 133.89% for FY-2014, is above with its 5-year median of -32.79%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	133.9	-9.5
Operating Profit Margin	-77.01	-9.44
Net Profit Margin	133.89	-32.79

Q.7 Debt to Equity ratio of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Debt-to-Equity ratio is 0.00, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.8 Debt to cash flow from operations of Mahavir Advanced Remedies Ltd?

Mahavir Advanced Remedies Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Mahavir Advanced Remedies Ltd?

Promoters hold 0.97% of the Mahavir Advanced Remedies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Mahavir Advanced Remedies Ltd vs industry peers?

Mahavir Advanced Remedies Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-	8.3
Gross Profit Growth	0	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.01	0.81
ROE	1.58	9.49
ROCE	1.58	11.91
Cash Conversion Cycle (days)	189.05	85

Valuation & price assessment

Q.1 Stock return of Mahavir Advanced Remedies Ltd over the last decade?

Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	-

Q.3 Valuation ratios of Mahavir Advanced Remedies Ltd vs historical?

The current P/E is similar that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	660.72	660.72	31.09
Price to Book	19.18	19.18	2.85
Price to Sales	838.85	838.85	2.79
EV to EBITDA	782.7	782.70	15.87

Check more companies

5. Wockhardt

8. Pfizer

10. Neuland Laboratories

Check trending companies

1. KEC International Ltd.

2. Aurobindo Pharma Ltd.

3. GE Vernova T&D India Ltd.

4. Avenue Supermarts Ltd.

5. Procter & Gamble Hygiene and Health Care Ltd.